AVITA Medical Inc
AVH: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| LOCK|T$$?$d | LOCK|R<L | LOCK|<>W>v!g |
Avita Medical Earnings: Profitability in Sight With Continued Progress in Cash Efficiency
Avita's 2025 results came in line with market expectations, with revenue up 11%, meeting guidance. Reiterated 2026 guidance implies an acceleration of revenue growth to 15% at the midpoint. Fourth-quarter 2025 cash burn fell to USD 5 million from USD 6 million in the third quarter.
